12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trajenta regulatory update

The Scottish Medicines Consortium recommended restricted the use of Trajenta linagliptin from Eli Lilly and Boehringer on the National Health Service (NHS) in Scotland to treat Type II diabetes. The consortium recommends the use of...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >